Alnylam Strengthens IP Position With Acquisition Of Nucleonics Patent Estate
This article was originally published in The Pink Sheet Daily
Executive Summary
RNAi-focused biotech calls acquisition inexpensive, will prevent potential end-around of its intellectual property.